Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 37

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 37
---
 Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd dated December 21, 2019
     
    10-Q
     
    001-14895
     
    10.1
     
    8/4/21

     10.55
     
    Amendment no. 14 dated October 31, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21, 2019
     
    10-K
     
    001-14895
     
    10.74
     
    2/28/24

     10.56^
     
    Amendment No. 2, dated November 17, 2021 to License Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. on the one hand and BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV on the other hand
     
    10-K
     
    001-14895
     
    10.66
     
    3/1/22

     10.57†
     
    Letter Agreement, dated November 18, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram
     
    10-K
     
    001-14895
     
    10.72
     
    2/28/23

     10.58
     
    Sarepta Therapeutics Inc.'s Policy for Recoupment of Incentive Compensation
     
    10-K
     
    001-14895
     
    10.77
     
    2/28/24

     10.59^
     
    Amended and Restated Lead DMD ProductManufacturing and Supply Agreement betweenCatalent Maryland, Inc. and Sarepta Therapeutics Three, LLC
     
    10-Q
     
    001-14895
     
    10.1
     
    8/2/23

     10.60^
     
    Exclusive License Agreement between the Research Institute at Nationwide Children's Hospital and Sarepta Therapeutics, Inc., dated October 8,